Potential health hazard โ use of or exposure to this product may cause temporary or medically reversible adverse health consequences.
Losartan Potassium Tablets Recalled by Legacy Pharmaceutical Packaging LLC Due to CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact Legacy Pharmaceutical Packaging LLC directly.
Affected Products
Losartan Potassium Tablets, USP, 50 mg, 30 tablet bottles, Rx Only, Distributed by: Wal-Mart, Bentonville, AR 72716, Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854, Packaged by: Legacy Pharmaceutical Packaging LLC, Earth City, MO 63045. NDC 68645-578-54
Quantity: 2,851,284 bottles
Why Was This Recalled?
CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected
Where Was This Sold?
This product was distributed to 5 states: AR, CA, GA, IN, MD
About Legacy Pharmaceutical Packaging LLC
Legacy Pharmaceutical Packaging LLC has 10 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc ยท March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. ยท March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC ยท February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC ยท February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC ยท February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report